Betulinic acid treatment promotes apoptosis in hepatoblastoma cells

International Journal of Oncology

Volumn 35, Issue 4, 2009, Pages 873-879

  Eichenmuller M ^a   Von Schweinitz, D ^a   Kappler, R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apoptosis; Betulinic acid; Hedgehog; Hepatoblastoma

Indexed keywords

BETULIC ACID; CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN PATCHED 1; SOMATOMEDIN B; SONIC HEDGEHOG PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR GLI2;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MORPHOLOGY; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE TARGETING; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HEDGEHOG PROTEINS; HEP G2 CELLS; HEPATOBLASTOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRITERPENES;

EID: 70449457428     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000402     Document Type: Article

References (43)

1. Mann JR, Kasthuri N, Raafat F, Pincott JR, Parkes SE, Muir KR, Ingram LC and Cameron AH: Malignant hepatic tumours in children: incidence, clinical features and aetiology. Paediatr Perinat Epidemiol 4: 276-289, 1990. (Pubitemid 20314325)
2. Litten JB and Tomlinson GE: Liver tumors in children. Oncologist 13: 812-820, 2008.
3. Weinberg AG and Finegold MJ: Primary hepatic tumors of childhood. Hum Pathol 14: 512-537, 1983.
4. Perilongo G, Shafford E and Plaschkes J: SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 1: 94-100, 2000.
5. Von Schweinitz D: Management of liver tumors in childhood. Semin Pediatr Surg 15: 17-24, 2006.
6. Hartmann W, Waha A, Koch A, Goodyer CG, Albrecht S, von Schweinitz D and Pietsch T: p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol 157: 1393-1403, 2000. (Pubitemid 30757959)
7. Honda S, Arai Y, Haruta M, Sasaki F, Ohira M, Yamaoka H, Horie H, Nakagawara A, Hiyama E, Todo S and Kaneko Y: Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. Br J Cancer 99: 1891-1899, 2008.
8. Rainier S, Dobry CJ and Feinberg AP: Loss of imprinting in hepatoblastoma. Cancer Res 55: 1836-1838, 1995.
9. Gray SG, Eriksson T, Ekstrom C, Holm S, von Schweinitz D, Kogner P, Sandstedt B, Pietsch T and Ekstrom TJ: Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 82: 1561-1567, 2000. (Pubitemid 30204363)
10. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928, 2008.
11. Yuan TL and Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510, 2008.
12. Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007.
13. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown DM, et al: Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1: 1046-1051, 1995.
14. Alakurtti S, Makela T, Koskimies S and Yli-Kauhaluoma J: Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci 29: 1-13, 2006. (Pubitemid 44279394)
15. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C and Formelli F: Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17-25, 2002. (Pubitemid 33153040)
16. Fulda S and Debatin KM: Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med Pediatr Oncol 35: 616-618, 2000.
17. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer PH, Peter ME and Debatin KM: Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57: 4956-4964, 1997. (Pubitemid 27469008)
18. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME and Debatin KM: Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 273: 33942-33948, 1998. (Pubitemid 29008858)
19. Sarek J, Klinot J, Dzubak P, Klinotova E, Noskova V, Krecek V, Korinkova G, Thomson JO, Janost'akova A, Wang S, Parsons S, Fischer PM, Zhelev NZ and Hajduch M: New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships. J Med Chem 46: 5402-5415, 2003.
20. Hartmann W, Digon-Sontgerath B, Koch A, Waha A, Endl E, Dani I, Denkhaus D, Goodyer CG, Sorensen N, Wiestler OD and Pietsch T: Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 12: 3019-3027, 2006. (Pubitemid 43837346)
21. Zumkeller W and Schwab M: Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis: potential diagnostic and therapeutic perspectives. Horm Metab Res 31: 138-141, 1999. (Pubitemid 29169488)
22. Fulda S, Jeremias I, Steiner HH, Pietsch T and Debatin KM: Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 82: 435-441, 1999. (Pubitemid 29302986)
23. Schmidt ML, Kuzmanoff KL, Ling-Indeck L and Pezzuto JM: Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer 33: 2007-2010, 1997.
24. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK and von Schweinitz D: Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74: 809-818, 1996. (Pubitemid 26117140)
25. Eichenmüller M, Gruner I, Hagl B, Häberle B, Müller-Höcker J, von Schweinitz D and Kappler R: Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 49: 482-490, 2009.
26. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
27. Cory S, Huang DC and Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607, 2003. (Pubitemid 38028528)
28. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle check-point by survivin. Nature 396: 580-584, 1998. (Pubitemid 28563719)
29. Niedzielska G and Kocki J: Evaluation of bcl-2 gene expression in papilloma of larynx in children. Int J Pediatr Otorhinolaryngol 53: 25-29, 2000. (Pubitemid 30336257)
30. Evangelista M, Tian H and De Sauvage FJ: The hedgehog signaling pathway in cancer. Clin Cancer Res 12: 5924-5928, 2006.
31. Ruiz i Altaba A, Sanchez P and Dahmane N: Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2: 361-372, 2002.
32. Huang S, He J, Zhang X, Bian Y, Yang L, Xie G, Zhang K, Tang W, Stelter AA, Wang Q, Zhang H and Xie J: Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 27: 1334-1340, 2006. (Pubitemid 43985408)
33. von Schweinitz D, Hecker H, Harms D, Bode U, Weinel P, Burger D, Erttmann R and Mildenberger H: Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma-a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 30: 845-852, 1995.
34. Scotting PJ, Walker DA and Perilongo G: Childhood solid tumours: a developmental disorder. Nat Rev Cancer 5: 481-488, 2005.
35. Udeani GO, Zhao GM, Geun Shin Y, Cooke BP, Graham J, Beecher CW, Kinghorn AD and Pezzuto JM: Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice. Biopharm Drug Dispos 20: 379-383, 1999. (Pubitemid 30449776)
36. Fulda S and Debatin KM: Sensitization for anticancer drug-induced apoptosis by betulinic Acid. Neoplasia 7: 162-170, 2005. (Pubitemid 40315993)
37. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA and Letai A: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365, 2006. (Pubitemid 43668734)
38. Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumori-genesis. J Clin Invest 114: 1117-1127, 2004. (Pubitemid 39578701)
39. Li D, Chen X and Zhang W: The inhibition of apoptosis of hepatoma cells induced by HBx is mediated by up-regulation of survivin expression. J Huazhong Univ Sci Technolog Med Sci 23: 383-386, 2003.
40. Warmann SW, Frank H, Heitmann H, Ruck P, Herberts T, Seitz G and Fuchs J: Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res 144: 43-48, 2008. (Pubitemid 350234956)
41. Zhang W, Chen X and Qiu F: An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy. J Huazhong Univ Sci Technolog Med Sci 23: 387-391, 2003.
42. Arai MA, Tateno C, Hosoya T, Koyano T, Kowithayakorn T and Ishibashi M: Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana. Bioorg Med Chem 16: 9420-9424, 2008.
43. Rubin LL and De Sauvage FJ: Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 5: 1026-1033, 2006.